Related Experiment Videos
Treatment of rheumatoid arthritis: etanercept a recent advance
1jaylar@worldpath.net
Purpose:
To review the specific mechanism of action of biologic response modifiers and help clinicians place these new drugs in the context of established therapies for rheumatoid arthritis (RA).
Data Sources:
Review of scientific literature, including all the clinical trials for these drugs.
Conclusions:
Biologic response modifiers target key inflammatory events involved in joint destruction. They have the potential to revolutionize the management of RA.
Implications For Practice:
Referral to a rheumatologist should be strongly considered as soon as the diagnosis of RA is made. Early referral to a specialist has been associated with improved health status for patients with RA due to early and aggressive therapy with these new agents.
Insights
Biologic response modifiers target inflammation in rheumatoid arthritis (RA). Early use of these drugs, alongside specialist care, may revolutionize RA management and improve patient outcomes.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and destruction.
- Established therapies for RA have limitations in managing disease progression and symptoms.
Purpose of the Study:
- To elucidate the mechanism of action of biologic response modifiers (BRMs).
- To guide clinicians in integrating BRMs into existing rheumatoid arthritis treatment paradigms.
Main Methods:
- Comprehensive review of scientific literature.
- Inclusion of all available clinical trials for biologic response modifiers.
Main Results:
- Biologic response modifiers effectively target critical inflammatory pathways driving joint damage in RA.
- These agents demonstrate significant potential in altering the disease course.
Conclusions:
- Biologic response modifiers represent a significant advancement in rheumatoid arthritis therapeutics.
- Early diagnosis and prompt referral to a rheumatologist for aggressive therapy with BRMs are crucial for improving patient health status.